| CASE REPORT |
|
| Year : 2012 | Volume
: 4
| Issue : 2 | Page : 128-131 |
|
|
Multisystem sarcoidosis in a patient on interferon-α therapy for chronic hepatitis C
Bouchra Oudghiri1, Mohammed Benzagmout2, Saïd Boujraf3, Faouzi Belahcen4, Adil Ibrahimi1
1 Department of Hepatogastroenterology, University Hospital of Fez, Morocco
2 Clinical Neurosciences Laboratory, Faculty of Medicine and Pharmacy of Fez; Department of Neurosurgery, University Hospital of Fez, Morocco
3 Clinical Neurosciences Laboratory, Department of Biophysics and Clinical MRI Methods, Faculty of Medicine and Pharmacy of Fez, Morocco
4 Department of Neurosurgery and Neurology, University Hospital of Fez, Morocco
Correspondence Address:
Saïd Boujraf
Clinical Neurosciences Laboratory, Department of Biophysics and Clinical MRI Methods, Faculty of Medicine and Pharmacy of Fez
Morocco
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-777X.96779
|
|
|
Sarcoidosis is a chronic multisystemic granulomatous disease that is triggered by an autoimmune process. Nowadays, this pathology represents a well-recognized but uncommon complication for antiviral treatment in hepatitis C virus (HCV) infection. Herein, we report a remarkable case of 47-year-old woman treated for chronic HCV infection; the patient has developed interferon alfa-induced sarcoidosis involving the central nervous system. The evolution was fatal despite disrupting the antiviral therapy and initiating a high-dose corticotherapy. This complication of interferon alfa treatment was reported in the literature in only one case. Through this case and a review of the literature, we aim to underline the importance of screening for sarcoidosis before and during the follow-up of HCV patients undergoing antiviral therapy. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
